Patap
EGFR Patent Analysis of PATENT#US11234567, PATENT#EP3456789 2025
CNS Penetration Breakthrough Opportunities
3,156
Active Patents
$28.3B
Market Potential
45%
CNS Whitespace
127
CNS Patents
CNS Penetration Breakthrough
$28.3B market opportunity in CNS-penetrant EGFR inhibitors for glioblastoma and brain metastases, with 45% patent whitespace.
127
CNS-specific patents identified
Strategic Market Position
Brain-penetrant inhibitors represent the highest-value EGFR opportunity with limited competition and clear clinical need.
$2.3B
Glioblastoma market value
Competitive Intelligence
3,156 total EGFR patents with concentrated competition in traditional inhibitors, creating CNS opportunity.
67%
Clinical success rate